Table 4 Palliation score

From: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

 

CE

SPE

 
 

Change from baseline

Change from baseline

 

Symptom

Mean (s.d.)

Median (range)

Mean (s.d.)

Median (range)

P a

Cough

−0.38 (1.16)

0 (−3 to 3)

−0.54 (1.06)

0 (−3 to 3)

0.51

Pain

−0.19 (1.00)

0 (−3 to 3)

−0.19 (0.96)

0 (−3 to 3)

0.96

Anorexia

−0.07 (1.16)

0 (−3 to 3)

0.08 (1.22)

0 (−3 to 3)

0.37

Shortness of

     

breath

−0.05 (1.02)

0 (−2 to 3)

−0.31 (0.95)

0 (−3 to 3)

0.12

Well-being

−0.15 (1.13)

0 (−3 to 3)

−0.02 (1.14)

0 (−3 to 3)

0.48

Nausea

0.16 (0.84)

0 (−2 to 3)

0.26 (0.80)

0 (−1 to 3)

0.21

Diarrhoea or

     

constipation

0.05 (1.07)

0 (−3 to 3)

0.04 (0.99)

0 (−3 to 3)

0.69

Sleep

−0.15 (1.08)

0 (−3 to 3)

−0.04 (0.89)

0 (−3 to 2)

0.10

Total

−0.80 (6.04)

−2 (−12 to 22)

−0.71 (5.35)

−1 (−15 to 21)

0.32

  1. CE, carboplatin plus etoposide; s.d., standard deviation; SPE, split doses of cisplatin plus etoposide.
  2. aWilcoxon rank-sum test.
Back to article page